This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Apr;10(4):198.

doi: 10.1038/nrrheum.2014.42. Epub 2014 Mar 11.

Vasculitis syndromes: phase III trial of infliximab in Kawasaki disease

Bryony M Mearns

PMID: 24614593
DOI: 10.1038/nrrheum.2014.42

Comment

Vasculitis syndromes: phase III trial of infliximab in Kawasaki disease

Bryony M Mearns. Nat Rev Rheumatol. 2014 Apr.

. 2014 Apr;10(4):198.

doi: 10.1038/nrrheum.2014.42. Epub 2014 Mar 11.

Author

Bryony M Mearns

PMID: 24614593
DOI: 10.1038/nrrheum.2014.42

No abstract available

PubMed Disclaimer

Comment on

Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC. Tremoulet AH, et al. Lancet. 2014 May 17;383(9930):1731-8. doi: 10.1016/S0140-6736(13)62298-9. Epub 2014 Feb 24. Lancet. 2014. PMID: 24572997 Clinical Trial.

References

1. Lancet. 2014 May 17;383(9930):1731-8 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information